MESO - Mesoblast

-

$undefined

N/A

(N/A)

Mesoblast NasdaqGS:MESO Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Location: 55 Collins Street, Melbourne, VIC, 3000, Australia | Website: https://www.mesoblast.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.4B

Cash

38.03M

Avg Qtr Burn

-10.64M

Short % of Float

0.41%

Insider Ownership

0.06%

Institutional Own.

3.10%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
RYONCIL™ (Remestemcel-L) Details
Acute graft-versus host disease

Approved

Quarterly sales

REVASCOR® (Rexlemestrocel) Details
Pediatric Hypoplastic Left Heart Syndrome (HLHS)

BLA

Submission

REVASCOR® (Rexlemestrocel) Details
Ischemic CHF with reduced ejection fraction (HFrEF) and inflammation

BLA

FDA meeting

Rexlemestrocel Details
Chronic lower back pain (CLBP)

Phase 3

Update

Failed

Discontinued

Remestemcel-L Details
Inflammatory bowel disease, Bowel disorder, Crohns disease

Failed

Discontinued